References
[1] Panza, F., M. Lozupone, G. Logroscino, and B.P. Imbimbo. (2019). A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol. 15:73-88. doi:10.1038/s41582-018-0116-6.
[2] El Ayadi, A., E.S. Stieren, J.M. Barral, and D. Boehning. (2013). Ubiquilin-1 and protein quality control in Alzheimer disease. Prion. 7:164-169. doi:10.4161/pri.23711.
[3] Hwang, G.-W., D. Sasaki, and A. Naganuma. (2005). Overexpression of Rad23 confers resistance to methylmercury in sac-charomyces cerevisiae via inhibition of the degradation of ubiquitinated proteins. Mol Pharmacol. 68:1074-1078.
doi:10.1124/mol.105.013516.
[4] Pickart, C.M., and D. Fushman. (2004). Polyubiquitin chains: polymeric protein signals. Current Opinion in Chemical Biology. 8:610–616. doi:10.1016/j.cbpa.2004.09.009.
[5] Nathan, J.A., H. Tae Kim, L. Ting, S.P. Gygi, and A.L. Goldberg. (2013). Why do cellular proteins linked to K63-polyubiquitin chains not associate with proteasomes? EMBO J. 32:552–565. doi:10.1038/emboj.2012.354.
[6] Marblestone, J.G., K.G. Suresh Kumar, M.J. Eddins, C.A. Leach, D.E. Sterner, M.R. Mattern, and B. Nicholson. (2010). Novel approach for characterizing ubiquitin E3 ligase function. J Biomol Screen. 15:1220–1228. doi:10.1177/1087057110380456.
[7] Raasi, S., and C.M. Pickart. (2003). Rad23 ubiquitin-associated domains (UBA) inhibit 26 S proteasome-catalyzed proteolysis by sequestering lysine 48-linked polyubiquitin chains. J Biol Chem. 278:8951–8959. doi:10.1074/jbc.m212841200.
[8] Kontaxi, C., P. Piccardo, and A.C. Gill. (2017). Lysine-Directed Post-translational Modifications of Tau Protein in Alzheimer’s Disease and Related Tauopathies. Front Mol Biosci. 4:56. doi:10.3389/fmolb.2017.00056.
[9] Naseri, N.N., H. Wang, J. Guo, M. Sharma, and W. Luo. (2019). The complexity of tau in Alzheimer’s disease. Neurosci Lett. 705:183–194. doi:10.1016/j.neulet.2019.04.022.
[10] He, Z., J.L. Guo, J.D. McBride, S. Narasimhan, H. Kim, L. Changolkar, B. Zhang, R.J. Gathagan, C. Yue, C. Dengler, A. Stieber, M. Nitla, D.A. Coulter, T. Abel, K.R. Brunden, J.Q. Trojanowski, and V.M.-Y. Lee. (2018). Amyloid-β plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat Med. 24:29–38. doi:10.1038/nm.4443.
[11] Zhang, Z., O. Obianyo, E. Dall, Y. Du, H. Fu, X. Liu, S.S. Kang, M. Song, S.-P. Yu, C. Cabrele, M. Schubert, X. Li, J.-Z. Wang, H. Brandstetter, and K. Ye. (2017). Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer’s disease. Nat Commun. 8:14740. doi:10.1038/ncomms14740.
[12] Mori, H., J. Kondo, and Y. Ihara. (1987). Ubiquitin is a component of paired helical filaments in Alzheimer’s disease. Science. 235:1641–1644. doi:10.1126/science.3029875.
[13] Cripps, D., S.N. Thomas, Y. Jeng, F. Yang, P. Davies, and A.J. Yang. (2006). Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem. 281:10825–10838. doi:10.1074/jbc.M512786200.
[14] Nakayama, Y., S. Sakamoto, K. Tsuji, T. Ayaki, F. Tokunaga, and H. Ito. (2019). Identification of linear polyubiquitin chain immunoreactivity in tau pathology of Alzheimer’s disease. Neurosci Lett. 703:53–57. doi:10.1016/j.neulet.2019.03.017.